MX2016017308A - Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades. - Google Patents

Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades.

Info

Publication number
MX2016017308A
MX2016017308A MX2016017308A MX2016017308A MX2016017308A MX 2016017308 A MX2016017308 A MX 2016017308A MX 2016017308 A MX2016017308 A MX 2016017308A MX 2016017308 A MX2016017308 A MX 2016017308A MX 2016017308 A MX2016017308 A MX 2016017308A
Authority
MX
Mexico
Prior art keywords
treatment
various diseases
cell
signal transduction
transduction pathway
Prior art date
Application number
MX2016017308A
Other languages
English (en)
Spanish (es)
Inventor
Combette Jean-Marc
Deloche Catherine
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/001881 external-priority patent/WO2014206427A1/en
Priority claimed from PCT/EP2014/002724 external-priority patent/WO2015197098A1/en
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Priority claimed from PCT/EP2015/001294 external-priority patent/WO2015197194A2/en
Publication of MX2016017308A publication Critical patent/MX2016017308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
MX2016017308A 2013-06-26 2015-06-26 Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades. MX2016017308A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2013/001881 WO2014206427A1 (en) 2013-06-26 2013-06-26 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP2013001896 2013-06-27
PCT/EP2014/001736 WO2014206563A2 (en) 2013-06-26 2014-06-26 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PCT/EP2014/002724 WO2015197098A1 (en) 2014-06-26 2014-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PCT/EP2015/001294 WO2015197194A2 (en) 2014-06-26 2015-06-26 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Publications (1)

Publication Number Publication Date
MX2016017308A true MX2016017308A (es) 2017-05-01

Family

ID=51033122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017308A MX2016017308A (es) 2013-06-26 2015-06-26 Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades.

Country Status (14)

Country Link
US (1) US10624948B2 (enExample)
EP (1) EP3013353B1 (enExample)
JP (3) JP2016523274A (enExample)
KR (1) KR20160023669A (enExample)
CN (1) CN105307670A (enExample)
AU (1) AU2014301631A1 (enExample)
BR (1) BR112016029413A2 (enExample)
CA (1) CA2903275A1 (enExample)
EA (1) EA201501080A1 (enExample)
ES (1) ES2870085T3 (enExample)
HK (1) HK1224225A1 (enExample)
MX (1) MX2016017308A (enExample)
PL (1) PL3013353T3 (enExample)
WO (1) WO2014206563A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3936141A3 (en) * 2015-01-23 2022-03-23 Erasmus University Rotterdam Medical Center Anti-senescence compounds and uses thereof
CN109303782A (zh) * 2018-10-24 2019-02-05 厦门大学 Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用
WO2021046652A1 (en) 2019-09-12 2021-03-18 The University Of British Columbia Inhibiting zd17-jnk interaction as a therapy for acute myocardial infarction
KR102151133B1 (ko) * 2019-12-27 2020-09-02 주식회사 인투앱 프로피오니박테리움 아크네스에 특이적으로 결합하는 신규한 항체 및 이의 용도
WO2022009698A1 (ja) * 2020-07-06 2022-01-13 学校法人東京薬科大学 ペプチドおよびそれを含む複合体
KR102273163B1 (ko) * 2020-09-10 2021-07-05 주식회사 파이안바이오테크놀로지 혈소판 유래 미토콘드리아의 수득 방법 및 이의 용도
CN113633662B (zh) * 2021-07-02 2023-09-26 中山大学附属口腔医院 线粒体移植在治疗牙周炎中的应用
CN117147251B (zh) * 2023-08-16 2024-04-26 四川大学 一种人类离体牙髓组织透明化方法

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195304B (it) 1981-12-22 1988-10-12 Anic Spa Metodo per la preparazione di gem-diammino derivati n-monoacilati
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
IT1190389B (it) 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IT1227907B (it) 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992018138A1 (en) 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
EP0632722A4 (en) 1992-03-20 1997-07-30 Baylor College Medicine DNA TRANSPORTATION SYSTEM AND INSTRUCTIONS FOR USE.
JP4074658B2 (ja) 1992-04-03 2008-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己構築ポリヌクレオチド送達システム
WO1994004562A1 (en) 1992-08-13 1994-03-03 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
EP0656950B1 (en) * 1992-08-21 1998-11-04 Biogen, Inc. Tat-derived transport polypeptides
EP0667786B1 (en) 1992-08-27 2004-01-21 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5545551A (en) 1992-08-28 1996-08-13 Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of pur protein
EP0693939A1 (de) 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
EP0767833A1 (en) 1995-04-25 1997-04-16 Baxter International Inc. Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
CA2227786A1 (en) 1995-07-28 1997-02-13 Marie Curie Cancer Care Transport proteins and their uses
AU7366896A (en) 1995-09-21 1997-04-09 Innapharma, Inc. Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6630351B1 (en) 1999-06-07 2003-10-07 Mirus Corporation Compositions and methods for drug delivery using pH sensitive molecules
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6187817B1 (en) 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998023781A1 (en) 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US5880261A (en) 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
AU6972798A (en) 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
JP4129298B2 (ja) 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
EP0897002A3 (en) 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
WO1999016787A1 (en) 1997-09-26 1999-04-08 Washington University Cell death agonists
US6420031B1 (en) 1997-11-03 2002-07-16 The Trustees Of Princeton University Highly transparent non-metallic cathodes
AU745579B2 (en) * 1997-10-20 2002-03-21 F. Hoffmann-La Roche Ag Bicyclic kinase inhibitors
US6270956B1 (en) 1997-12-11 2001-08-07 The Salk Institute For Biological Studies Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CA2330458A1 (en) 1998-04-29 1999-11-04 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
EP1076711A2 (en) 1998-05-13 2001-02-21 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO1999058561A1 (fr) 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Mimotopes du virus de l'hepatite c
US6740524B1 (en) 1998-06-18 2004-05-25 Dnavec Research, Inc. Nucleic acid transfer phage
AU755564B2 (en) 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
EP1107998B1 (en) 1998-08-28 2004-02-04 Gryphon Sciences Method for the preparation of polyamide chains of precise length, their conjugates with proteins
JP2002525329A (ja) 1998-09-25 2002-08-13 セフアロン・インコーポレーテツド 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する／処置するための方法
US20020090696A1 (en) 1998-12-08 2002-07-11 Miller Carol A. Treating neurological disorders using human apoptosis inhibiting protein
US6656474B1 (en) 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
JP2003506071A (ja) 1999-05-28 2003-02-18 アポプトシス テクノロジー，アイエヌシー． アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP2269654A3 (en) 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
EP1210362A2 (en) 1999-09-01 2002-06-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP1242118B1 (en) 1999-12-16 2009-11-11 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
ATE508138T1 (de) 2000-06-16 2011-05-15 Serodus As N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
EP1345956A2 (en) 2000-10-13 2003-09-24 University of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
ES2386505T3 (es) 2000-10-17 2012-08-22 Diatranz Otsuka Limited Preparación y xenotrasplante de islotes de cerdo
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
MXPA03007358A (es) 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
JP4234999B2 (ja) 2001-04-06 2009-03-04 トマス ジェファソン ユニバーシティ 治療標的としてのｈｉｖ−１ｖｉｆタンパク質の多量体形成
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
AU2002322519A1 (en) 2001-07-17 2003-03-03 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7635681B2 (en) 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
CA2488013A1 (en) * 2002-05-30 2003-12-11 Celgene Corporation Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JP2004066595A (ja) 2002-08-05 2004-03-04 Canon Finetech Inc 記録装置およびレジストレーション用パターンの記録方法
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
EP1408114B1 (de) 2002-10-11 2007-01-03 Imvision GmbH Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
US20040186052A1 (en) * 2002-10-24 2004-09-23 Suhasini Iyer Cytomodulating peptides and methods for treating neurological disorders
ZA200503242B (en) * 2002-10-24 2006-10-25 Celgene Corp Treatment of pain with JNK inhibitors
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
JP4787150B2 (ja) 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｊｎｋ阻害剤
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US20050048995A1 (en) 2003-08-25 2005-03-03 Motorola, Inc. System and method for controlling the operating characteristics of a buffer
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
AU2005230416B2 (en) 2004-04-08 2010-05-13 Merck Serono Sa Composition comprising a JNK inhibitor and cyclosporin
WO2006021458A2 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1656951A1 (en) 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
US20100256041A1 (en) 2004-11-12 2010-10-07 Christophe Bonny Conjugate Molecule Compounds With Enhanced Cell Uptake Activity
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
ZA200706662B (en) * 2005-01-13 2009-04-29 Signal Pharmaceiticals Llc Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
CA2606110A1 (en) 2005-04-29 2006-12-07 Celgene Corporation Solid forms of 1-(5-(1h-1,2,4-triazol-5-yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene
US20070015779A1 (en) 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US10045953B2 (en) 2006-07-06 2018-08-14 Case Western Reserve University Ceramide composition and method of use
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
WO2008094208A2 (en) * 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
JP5325783B2 (ja) 2006-09-08 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー ベンゾトリアゾールキナーゼモジュレーター
EP2074138A4 (en) 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
GB0702259D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
DK2282779T3 (da) 2008-04-29 2013-05-27 Pharnext Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
CN105664136A (zh) 2008-05-07 2016-06-15 加利福尼亚大学董事会 眼表润滑的治疗性补充和富集
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US20100183633A1 (en) 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2381934A2 (en) 2008-12-23 2011-11-02 Carmel - Haifa University Economic Corp Ltd. Improving cognitive function
US8450363B2 (en) * 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
JP2010254672A (ja) * 2009-03-30 2010-11-11 Santen Pharmaceut Co Ltd ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤
JP5784604B2 (ja) * 2009-08-10 2015-09-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊｎｋ阻害剤
RU2012120783A (ru) 2009-10-22 2013-11-27 Женентек, Инк. Модуляция дегенерации аксона
US20130190244A1 (en) 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
RU2012155144A (ru) * 2010-06-04 2014-07-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
PL2902035T3 (pl) 2010-10-14 2019-04-30 Xigen Inflammation Ltd Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013079213A1 (en) 2011-11-30 2013-06-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
JP2015197193A (ja) 2014-04-02 2015-11-09 トヨタ自動車株式会社 車両用無段変速機の油圧制御装置
EP3160989A2 (en) 2014-06-26 2017-05-03 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US20180170983A1 (en) 2015-06-26 2018-06-21 Xigen Inflammation Ltd. New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment

Also Published As

Publication number Publication date
US10624948B2 (en) 2020-04-21
JP2020055866A (ja) 2020-04-09
JP2016523274A (ja) 2016-08-08
WO2014206563A2 (en) 2014-12-31
CA2903275A1 (en) 2014-12-31
BR112016029413A2 (pt) 2017-10-17
EP3013353A2 (en) 2016-05-04
KR20160023669A (ko) 2016-03-03
PL3013353T3 (pl) 2021-09-20
HK1224225A1 (zh) 2017-08-18
AU2014301631A1 (en) 2015-08-27
ES2870085T3 (es) 2021-10-26
WO2014206563A3 (en) 2015-03-19
JP2017520571A (ja) 2017-07-27
US20160199444A1 (en) 2016-07-14
EP3013353B1 (en) 2021-04-21
EA201501080A1 (ru) 2016-07-29
CN105307670A (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
MX2016017308A (es) Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades.
MX2014006399A (es) Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
UA98101C2 (ru) Пептидные ингибиторы пути трансдукции сигнала jnk, которые имеют способность проникать в клетку
JOP20220242A1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX365864B (es) Inhibidores de bromodominio biciclicos novedosos.
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
PT2491942E (pt) Utilização de inibidores peptídicos aos quais as células são permeáveis da via de transdução de sinal de jnk para o tratamento de várias doenças cardiovasculares
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201792047A1 (ru) Новые соединения
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
WO2015197194A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
TN2018000180A1 (en) Polypeptides inhibiting cd40l
MX369349B (es) Metodos para hacer inhibidores de la proteina deacetilasa.
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
EA201692038A1 (ru) Способы и композиции для лечения сосудистой мальформации
EA202091567A1 (ru) Химерные белки мти
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
WO2016055160A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PH12017502345A1 (en) Novel thrombin inhibitors
AU2013263786B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1